Christopher N Andrews1, Sacha Sidani2, John K Marshall3. 1. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. 3. Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: A growing body of evidence suggests that dysbiosis contributes to the onset and symptomatology of irritable bowel syndrome (IBS) and other functional bowel disorders. Changes to the gastrointestinal microbiome may contribute to the underlying pathophysiology of IBS. METHODS: The present review summarizes the potential effects of microbiome changes on GI transit, intestinal barrier function, immune dysregulation and inflammation, gut-brain interactions and neuropsychiatric function. RESULTS: A multimodal approach to IBS management is recommended in accordance with current Canadian guidelines. Pharmacologic treatments are advised to target the presumed underlying pathophysiological mechanism, such as dysregulation of GI transit, peristalsis, intestinal barrier function and pain signalling. The management plan for IBS may also include treatments directed at dysbiosis, including dietary modification and use of probiotics, which may promote the growth of beneficial bacteria, affect intestinal gas production and modulate the immune response; and the administration of periodic short courses of a nonsystemic antibiotic such as rifaximin, which may re-establish microbiota diversity and improve IBS symptoms. CONCLUSION: Dysregulated host-microbiome interactions are complex and the use of microbiome-directed therapies will necessarily be empiric in individual patients. A management algorithm comprising microbiome- and nonmicrobiome-directed therapies is proposed.
BACKGROUND: A growing body of evidence suggests that dysbiosis contributes to the onset and symptomatology of irritable bowel syndrome (IBS) and other functional bowel disorders. Changes to the gastrointestinal microbiome may contribute to the underlying pathophysiology of IBS. METHODS: The present review summarizes the potential effects of microbiome changes on GI transit, intestinal barrier function, immune dysregulation and inflammation, gut-brain interactions and neuropsychiatric function. RESULTS: A multimodal approach to IBS management is recommended in accordance with current Canadian guidelines. Pharmacologic treatments are advised to target the presumed underlying pathophysiological mechanism, such as dysregulation of GI transit, peristalsis, intestinal barrier function and pain signalling. The management plan for IBS may also include treatments directed at dysbiosis, including dietary modification and use of probiotics, which may promote the growth of beneficial bacteria, affect intestinal gas production and modulate the immune response; and the administration of periodic short courses of a nonsystemic antibiotic such as rifaximin, which may re-establish microbiota diversity and improve IBS symptoms. CONCLUSION: Dysregulated host-microbiome interactions are complex and the use of microbiome-directed therapies will necessarily be empiric in individual patients. A management algorithm comprising microbiome- and nonmicrobiome-directed therapies is proposed.
Authors: Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova Journal: World J Gastroenterol Date: 2010-06-28 Impact factor: 5.742
Authors: Claudia R Cavaglieri; Anita Nishiyama; Luis Claudio Fernandes; Rui Curi; Elizabeth A Miles; Philip C Calder Journal: Life Sci Date: 2003-08-15 Impact factor: 5.037
Authors: Johannes Peter; Camille Fournier; Marija Durdevic; Lukas Knoblich; Bettina Keip; Clemens Dejaco; Michael Trauner; Gabriele Moser Journal: Psychosom Med Date: 2018-10 Impact factor: 4.312
Authors: Francesca Curci; Filomena Corbo; Maria Lisa Clodoveo; Lara Salvagno; Antonio Rosato; Ivan Corazza; Roberta Budriesi; Matteo Micucci; Laura Beatrice Mattioli Journal: Nutrients Date: 2022-03-16 Impact factor: 5.717